Edinburgh, UK, 22nd June 2018 / Synpromics, the leader in gene control, is delighted to announce that David Venables, CEO of the Company, has won the ‘Disruptor’ category of Scotland’s EY Entrepreneur Of The Year 2018. 


In May, Synpromics attended the ASGCT annual general meeting in Chicago. After a slightly delayed arrival of the exhibition stands (having got temporarily lost somewhere over the Atlantic!), the Synpromics delegation enjoyed a few days of interesting presentations around the future of gene and cell therapy, as well as making some great connections with fellow biotech professionals. Synpromics were also able to introduce numerous booth visitors to a renowned Scottish delicacy, the Tunnocks Teacake – 500 were consumed over the course of the conference!

Flavia Scialpi

Making the step from academia into industry can seem daunting and can appear to require a very different skill set. Flavia Scialpi, Head of Biology at Synpromics, discusses how she used her experiences to make this transition in a recent blog post for Nature Jobs. Click here to read the article in full and learn more about Flavia’s career path and how setbacks may in fact be opportunities in disguise.


In April, Synpromics attended the 6th annual Alliance for Regenerative Medicine Cell & Gene Therapy Investor Day in New York, a full-day conference featuring discussions between key opinion leaders, top analysts and senior executives in addition to presentations by the field’s most promising companies. Whilst there, David Venables, CEO of Synpromics, presented to potential investors and fellow biotech professionals. 


Edinburgh, UK, 3rd May 2018 / Synpromics Ltd, the leader in gene control, today announced it has been awarded a £1.9m research and development grant from Scottish Enterprise. The funds will expand Synpromics’ world leading R&D programmes in gene regulation for cell and gene medicines.